Cargando…
Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities—a practical review
Prophylactic therapy with exogenous clotting factor concentrates in haemophilia A and B aims to achieve levels of circulating FVIII or FIX that are adequate for the prevention or reduction of spontaneous joint bleeding. Historically, a minimum trough level of at least 1% of the normal levels of circ...
Autores principales: | Hermans, Cedric, Dolan, Gerry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594230/ https://www.ncbi.nlm.nih.gov/pubmed/33194165 http://dx.doi.org/10.1177/2040620720966888 |
Ejemplares similares
-
Pain and pain management in haemophilia
por: Auerswald, Günter, et al.
Publicado: (2016) -
Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders
por: Kaczmarek, Radoslaw, et al.
Publicado: (2021) -
Emicizumab in acquired haemophilia A: about two clinical cases and literature review
por: Hansenne, Amandine, et al.
Publicado: (2021) -
Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients
por: Ljung, Rolf, et al.
Publicado: (2018) -
Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)